ArticleFrontiers in pediatrics2025
Therapeutic plasma exchange in autoimmune diseases: a retrospective study in a tertiary pediatric hospital in Mexico.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the use and mortality-associated factors of therapeutic plasma exchange (TPE) in children with autoimmune diseases at a tertiary pediatric hospital in Mexico. Methods: Retrospective cross-sectional study including patients under 18 years old with autoimmune diseases who underwent TPE between 2022 and 2025 at the Hospital Infantil de México Federico Gómez. Demographic, clinical, therapeutic, and laboratory data were analyzed. Clinical response and mortality-associated factors were assessed. Results: Forty-one patients were included (68% female; median age: 12 years). The most frequent indications for TPE were systemic lupus erythematosus (SLE) (56.1%) and autoimmune encephalitis (14.6%). Other diagnoses included macrophage activation syndrome (MAS) ( Conclusion: TPE was safe and beneficial in children with severe autoimmune diseases. Mortality was related to disease duration rather than the procedure itself.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.